Yunnan Baiyao To Acquire Xishuangbanna Pharma For RMB 11.6 Million
This article was originally published in PharmAsia News
Yunnan Baiyao will enter a new sector of the medicine industry with a RMB 11.6 million deal to acquire Xishuangbanna Pharmaceutical
You may also be interested in...
EU Regulatory Roundup, February 2020: Brexit And Swixit Threaten Huge Disruption Amidst MDR Uncertainty
Complying with the EU’s new Medical Device Regulation would be hard enough. But more layers of uncertainty – especially Brexit and Swixit ̶ mean European medtech is navigating very turbulent waters right now.
Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.
Fresenius Kabi and Vifor Pharma have agreed to create a joint venture in China for intravenous iron products.